Schools

Texas Chemists' Powerful New Pain Reliever Could Help End Opioid Abuse

UT-Austin chemists helped find a pathway for a new, potent, synthetic compound that may end addiction to opioids for relief of chronic pain.

AUSTIN, TX — A team of scientists led by University of Texas at Austin chemists have discovered a powerful pain reliever acting through a previously unknown anatomical pathway.

UT-Austin chemists Stephen Martin and James Sahn are on the scientific team making the discovery. Central to the discovery is the synthetic compound known as UKH-1114 which is as effective at relieving neuropathic pain in injured mice as a drug widely used for pain relief called gabapentin. But it works at a much lower dose, with longer duration of action, chemists noted.

If the researchers can demonstrate that the drug is safe, effective and nonaddictive in humans — a process that typically takes years — the discovery could be instrumental in addressing one of today’s biggest public health challenges: the opioid abuse epidemic, university officials said.

Find out what's happening in Austinwith free, real-time updates from Patch.

Nearly a third of Americans suffer from chronic pain, yet the most effective pain relievers — opioids — are addictive and often require increased dosing to maintain efficacy. According to the National Institute on Drug Abuse, some 2 million people in the U.S. suffer from addiction to prescription opioid pain relievers, according to university-provided data. But chemists note that alternatives to opioids have their own drawbacks — for example, gabapentin (sold as Neurontin) can cause cognitive impairment in certain individuals.

“This opens the door to having a new treatment for neuropathic pain that is not an opioid,” said Martin, a professor and the M. June and J. Virgil Waggoner Regents Chair in Chemistry. “And that has huge implications.”

Find out what's happening in Austinwith free, real-time updates from Patch.

The pain drug they found binds to a receptor on cells throughout the central nervous system called the sigma 2 receptor. Although it was discovered 25 years ago, scientists still did not know what sigma 2 did until now, chemists said.

Theodore Price, associate professor of neuroscience at The University of Texas at Dallas and a leading expert on chronic pain, tested UKH-1114 on mice with nerve damage and found that it alleviated pain as well as gabapentin did, but at a much lower dose (one-sixth as much) and was effective much longer (lasting for a couple of days, compared with 4 to 6 hours), officials said. This research is the first to demonstrate that the sigma 2 receptor may be a target for treating neuropathic pain, according the the chemists' findings.

Results are published in the Aug. 18 print edition of the journal ACS Chemical Neuroscience. An earlier paper, published online on May 28 in the journal Proceedings of the National Academy of Sciences, described the molecular cloning and identification of the sigma 2 receptor.

University officials noted the researchers have filed patent applications on the new compound.

Neuropathic pain, or chronic pain, is caused when nerves in the central nervous system are damaged. Among other things, such pain can result from chemotherapy, diabetes and injuries to the brain or spinal cord.

But scientists noted much work remains to be done before UKH-1114 can enter the market, including additional studies needed to demonstrate safety, efficacy and oral bioavailability. In the meantime, the scientists are working to understand, on a fundamental level, how activating the sigma 2 receptor relieves neuropathic pain, officials said.

Despite that unforgiving schedule, the UT-Austin chemists expressed excitement over the compelling results from the mouse model.

“We started out just working on fundamental chemistry in the lab,” said Sahn, a research scientist in the Department of Chemistry. “But now we see the possibility that our discoveries could improve the quality of people’s lives. That is very satisfying.”

>>> Uppermost image: Stephen Martin (left) and James Sahn have discovered a new pain reliever that acts on a previously unknown pain pathway, photo courtesy of University of Texas at Austin


Get more local news delivered straight to your inbox. Sign up for free Patch newsletters and alerts.

We’ve removed the ability to reply as we work to make improvements. Learn more here